Analyst rates Tandem Diabetes Care a Hold: Q3 revenue rose 13.8%, but U.S.
Investing.com -- Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rose 8% after the company announced U.S. Food and Drug Administration clearance for its Tandem Mobi insulin pump to operate as a tubeless automated insulin delivery system with up to seven days of wear.
Tandem Diabetes Care shares rise 12% after FDA clears its tubeless Mobi system for up to seven days of wear; U.S.
Tandem Diabetes Care has been through a bruising stretch, with the share price down about 87.2% over the past five years, and yet the business still commands meaningful attention in insulin pump therapy. With that kind of long term decline and fresh headlines around its devices, the question now is whether the current valuation is properly supported by the cash flows the company is expected to generate. The roughly 87.2% share price decline over five years puts past investors under pressure...
Tandem Diabetes Care Inc (TNDM) posts 14% revenue growth and record pump shipments while recalibrating 2027 outlook on slower pharmacy adoption and CEO transition.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 13.8% year on year to $283.7 million. The company expects the full year’s revenue to be around $1.08 billion, close to analysts’ consensus estimates. Its GAAP loss of $0.10 per share was 60.2% above analysts’ consensus estimates.
Tandem Diabetes Care shares have climbed back from a deep multi year slump, which puts a fresh spotlight on what investors are paying for each dollar of the company’s sales today. With the stock changing hands at about US$18.90, the key issue is how that price lines up with the underlying revenue base. The share price is still down about 86.2% over 5 years, which makes the current valuation conversation heavily anchored on whether the business now generates enough sales to support a...
Tandem Diabetes Care (NASDAQ:TNDM) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time
Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...
Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.
Tandem Diabetes Care's (TNDM) Mobi automated insulin delivery system is now available in 12 countrie
MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
Tandem Diabetes Care (TNDM) has an average rating of overweight and mean price target of $29, accord
Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.
Tandem Diabetes Care (TNDM) is back in focus after recent share price swings, with the stock closing at US$16.87. Investors are weighing mixed return figures and fresh financial data on revenue and profit. The share price of US$16.87 comes after a sharp 24.42% decline in the 1 month share price return. However, the 3 month share price return is up 17.64%, and the 1 year total shareholder return of 34.21% indicates momentum that has been building over a longer period, despite weaker 3 and 5...
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
This is the newest page. Registered accounts read further back.